Clinical Value of Serum miRNA in Patients with Acute Promyelocytic Leukemia

Abstract

Objective. To explore the clinical value of specific miRNA in patients with acute promyelocytic leukemia. Methods. 129 patients with acute promyelocytic leukemia diagnosed in our hospital from January 2015 to January 2020 were selected as the observation group. At the same time, 74 patients with nonacute promyelocytic leukemia who underwent bone marrow aspiration were included as the control group. The expression levels of miR-126-5p and miR-13, different characteristic parameters, and prognosis were compared between the two groups, and the clinical significance of miR-126-5p and miR-13 in acute promyelocytic leukemia was analyzed. Results. The expression of miR-126-5p ( 12.31 ± 2.25 versus 17.30 ± 3.28 ) and miR-13 ( 16.05 ± 3.47 versus 21.66 ± 2.18) in the observation group was significantly lower than that in the control group ( P < 0.05 ). The expression level of miR-126-5p was significantly correlated with lactate dehydrogenase level, HGB level, NPM1 mutant type, and complete remission ( P < 0.05 ). The expression level of miR-13 was significantly correlated with HGB level, NPM1 mutant type, and complete remission ( P < 0.05 ). Both expression levels of miR-126-5p and miR-13 were not correlated with sex, age, WBC, PLT, proportion of bone marrow primordial cells, hepatomegaly, splenomegaly, lymph node enlargement, and FLT3-ITD ( P > 0.05 ). Cox multivariate regression analysis showed that peripheral blood WBC, bone marrow blast cell count, and miR-126-5p and miR-13 were prognostic factors in patients with acute promyelocytic leukemia ( P < 0.05 ). The sensitivity, specificity, accuracy, and AUC of serum miR-126-5p prediction were 75.83%, 84.56%, 82.17%, and 0.729, respectively. The sensitivity, specificity, accuracy, and AUC of serum miR-13 prediction were 78.64%, 88.49%, 86.20% and 0.882, respectively. Conclusion. Serum miR-126-5p and miR-13 are closely related to the prognosis of patients with acute promyelocytic leukemia. Serum miR-126-5p and miR-13 can be used as reliable indexes to predict the prognosis of patients.

The miR‐126‐5p and miR‐212‐3p in the extracellular vesicles activate monocytes in the early stage of radiation‐induced vascular inflammation implicated in atherosclerosis

“…Consistently, treatment with the miR‐126‐5p mimic enhanced the differentiation of monocytes to macrophages following PMA stimuli, and the subsequent transformation. Moreover, miR‐126‐5p has been proposed as a pathological indicator of several inflammation‐related diseases such as hypertension, acute myeloid leukemia, hepatoblastoma and type 1 diabetes (Chekka et al., 2022 ; Coulson et al., 2021 ; Hu et al., 2021 ; Zhang et al., 2022 ). Interestingly, the levels of miR‐126‐5p in plasma EVs were significantly increased in response to radiation exposure in our atherosclerosis model mice.…”